Albany Molecular Research Inc. (NASDAQ:AMRI) SVP Lori M. Henderson sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $17.00, for a total transaction of $102,000.00. Following the sale, the senior vice president now owns 51,337 shares in the company, valued at approximately $872,729. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Albany Molecular Research Inc. (NASDAQ:AMRI) traded down 0.12% during trading on Friday, reaching $17.32. 52,611 shares of the company’s stock were exchanged. Albany Molecular Research Inc. has a 52 week low of $12.45 and a 52 week high of $20.65. The company’s 50 day moving average price is $16.41 and its 200-day moving average price is $14.97. The stock’s market capitalization is $720.34 million.

Albany Molecular Research (NASDAQ:AMRI) last released its earnings results on Tuesday, November 8th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.04. The business had revenue of $151.70 million for the quarter, compared to the consensus estimate of $160.75 million. Albany Molecular Research had a negative net margin of 10.48% and a positive return on equity of 7.25%. The firm’s quarterly revenue was up 45.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.12) earnings per share. On average, equities analysts expect that Albany Molecular Research Inc. will post $1.08 EPS for the current year.

Separately, Morgan Stanley reaffirmed a “buy” rating and set a $17.00 price target on shares of Albany Molecular Research in a research note on Friday, August 5th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMRI. Louisiana State Employees Retirement System increased its position in Albany Molecular Research by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,000 shares of the company’s stock valued at $161,000 after buying an additional 100 shares during the period. Eqis Capital Management Inc. increased its position in Albany Molecular Research by 0.5% in the third quarter. Eqis Capital Management Inc. now owns 19,535 shares of the company’s stock valued at $323,000 after buying an additional 102 shares during the period. State Board of Administration of Florida Retirement System increased its position in Albany Molecular Research by 1.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 12,318 shares of the company’s stock valued at $166,000 after buying an additional 140 shares during the period. Rhumbline Advisers increased its position in Albany Molecular Research by 0.7% in the third quarter. Rhumbline Advisers now owns 37,114 shares of the company’s stock valued at $613,000 after buying an additional 250 shares during the period. Finally, Arizona State Retirement System increased its position in Albany Molecular Research by 2.2% in the second quarter. Arizona State Retirement System now owns 14,086 shares of the company’s stock valued at $189,000 after buying an additional 300 shares during the period. 74.30% of the stock is currently owned by institutional investors and hedge funds.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

5 Day Chart for NASDAQ:AMRI

Receive News & Stock Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related stocks with our FREE daily email newsletter.